for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sartorius Stedim Biotech SA

STDM.PA

Latest Trade

127.70EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

79.65

 - 

150.70

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
127.70
Open
--
Volume
--
3M AVG Volume
1.33
Today's High
--
Today's Low
--
52 Week High
150.70
52 Week Low
79.65
Shares Out (MIL)
92.18
Market Cap (MIL)
12,038.73
Forward P/E
46.03
Dividend (Yield %)
0.35

Next Event

Sartorius AG at Landesbank Baden Wuerttemberg Roadshow - Stuttgart

Latest Developments

More

Sartorius Stedim Biotech 9-Month EBITDA Up At EUR 312.3 Mln

Sartorius Stedim Biotech Signs Agreement To Acquire Parts Of Danaher Life Science

Sartorius Stedim Biotech H1 Underlying EBITDA At EUR 205.3 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sartorius Stedim Biotech SA

Sartorius Stedim Biotech SA is a France-based international provider of laboratory and process technologies and equipment. The Company covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The Company operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.

Industry

Medical Equipment & Supplies

Contact Info

Avenue de Jouques

Zone Industrielle les Paluds, C.S. 9105

Aubagne Cedex

+33.4.42845600

https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa

Executive Leadership

Joachim Kreuzburg

Chairman of the Board and Chief Executive Officer, Chairman of the Executive Committee

Liliane de Lassus

Non-Executive Director

Lothar Kappich

Non-Executive Director

Bernard Lemaitre

Non-Executive Director

Susan Dexter

Non-Executive Independent Director

Key Stats

3.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

1.1K

2017

1.1K

2018

1.2K

2019(E)

1.4K
EPS (EUR)

2016

1.920

2017

1.960

2018

2.380

2019(E)

2.837
Price To Earnings (TTM)
50.42
Price To Sales (TTM)
9.01
Price To Book (MRQ)
10.95
Price To Cash Flow (TTM)
39.35
Total Debt To Equity (MRQ)
15.54
LT Debt To Equity (MRQ)
7.40
Return on Investment (TTM)
20.33
Return on Equity (TTM)
14.97

Latest News

Latest News

BRIEF-Lonza Selects Sartorius Stedim Biotech As Preferred Supplier

* SARTORIUS STEDIM BIOTECH AND LONZA MODIFY RELATIONSHIP FOR SUPPLY OF CELL CULTURE MEDIA

BRIEF-Lonza, Sartorius Modify Relationship For Supply Of Cell Culture Media

Lonza And Sartorius Stedim Biotech Modify Relationship For Supply Of Cell Culture Media:

BRIEF-Sartorius Stedim Biotech Net Profit Up at 47.1 Million Euros

* IN Q1 INCREASED ITS SALES REVENUE IN CONSTANT CURRENCIES BY 9.8% (REPORTED 4.6%) TO 281.1 MILLION EUROS.

BRIEF-Sartorius Stedim Biotech And Penn State University Entered Into Collaborative Partnership

* SARTORIUS STEDIM BIOTECH AND PENN STATE UNIVERSITY ENTERED INTO COLLABORATIVE PARTNERSHIP TO ADVANCE MULTIDISCIPLINARY TEACHING AND RESEARCH IN BIOTECHNOLOGY Source text : https://bit.ly/2qygOm0 Further company coverage: (Gdynia Newsroom)

BRIEF-Sartorius Stedim Biotech Launches New Ambr 250 High Throughput Bioreactor System

* LAUNCHES NEW AMBR 250 HIGH THROUGHPUT BIOREACTOR SYSTEM FOR PERFUSION CULTURE Source text: http://bit.ly/2FKA8C8 Further company coverage: (Gdynia Newsroom:)

BRIEF-Sartorius Stedim Biotech 2017 Underlying EBITDA Up By 2.2%

* SARTORIUS STEDIM BIOTECH TARGETS CONTINUED PROFITABLE GROWTH - SALES REVENUE PROJECTED AT AROUND 2.8 BILLION EUROS IN 2025

BRIEF-Sartorius Stedim Biotech Proposes Dividend For Fiscal 2017 Of 0.46 Euro Per Share

* UNDER THIS PROPOSAL, TOTAL PROFIT DISTRIBUTED WOULD RISE BY 9.5% FROM EUR 38.7 MILLION TO EUR 42.4 MILLION. Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

BRIEF-Sartorius Stedim Biotech FY EBITDA Up At 294.9 Million Euros

* FY EBITDA EUR 294.9 MILLION VERSUS EUR 288.7 MILLION YEAR AGO

BRIEF-Abzena Selects Sartorius Stedim Biotech To Equip Sites In San Diego And Bristol

* ABZENA SELECTS SARTORIUS STEDIM BIOTECH TO EQUIP US BASED DVLPT AND MANUFACTURING SITES IN SAN DIEGO AND BRISTOL

BRIEF-Sartorius Stedim Biotech 9-month EBITDA up at 216.2 million euros

* 9 MONTHS SALES REVENUE EUR 806.5 MILLION VERSUS EUR 785.1 MILLION YEAR AGO

BRIEF-Sartorius Stedim Biotech Lothar Kappich appointed to board

* Sartorius Stedim Biotech: Lothar Kappich appointed to the board of directors Source text for Eikon: Further company coverage:

BRIEF-Sartorius Stedim Biotech 2017 first-half figures

* H1 SALES EUR 546.7 MILLION VERSUS EUR 508.8 MILLION YEAR AGO

BRIEF-Sartorius Stedim Biotech, PACA region and Aix-Marseille Provence Metropolis launch 23 million euros R & D program

* Provence-Alpes-Côte d'Azur region, Aix-Marseille Provence Metropolis and co launch 23 million euros R & D program in Aubagne

BRIEF-Sartorius Stedim Biotech proposes to increase dividend by 26 pct

* Proposal to annual general shareholders` meeting to increase dividend by 26.0 pct to 0.42 euro ($0.4425) per share Source text for Eikon: Further company coverage: ($1 = 0.9492 euros) (Gdynia Newsroom)

BRIEF-Sartorius Stedim Biotech FY net profit up 26.8 pct at 176.6 mln euros

* FY order intake 1.08 billion euros ($1.16 billion) versus 946.4 million euros year ago

BRIEF-Sartorius Stedim Biotech 9-month EBITDA rises to 214.1 million euros

* 9-month revenue 785.1 million euros ($853.56 million) versus eur 660.9 million year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up